What causes hht

Overview

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a genetic disorder that affects blood vessels. It is characterized by the abnormal development of blood vessels, particularly the formation of arteriovenous malformations (AVMs). These AVMs are essentially abnormal connections between arteries and veins, bypassing the capillaries that normally regulate blood flow and pressure. The walls of these AVMs are thin and fragile, making them prone to rupture and bleeding. This can lead to a variety of symptoms, most commonly recurrent nosebleeds (epistaxis) and bleeding from the gastrointestinal tract. Other affected areas can include the lungs, brain, liver, and skin, leading to a wide spectrum of potential complications.

What Causes HHT? The Genetic Basis

The root cause of HHT lies in inherited genetic mutations. These mutations are typically found in genes that play crucial roles in the development and maintenance of blood vessels. The process of forming new blood vessels (angiogenesis) and the maturation of existing ones is complex, involving intricate signaling pathways. When genes involved in these pathways are mutated, the resulting blood vessels can be malformed, fragile, and prone to bleeding.

Key Genes Involved in HHT

The vast majority of HHT cases are linked to mutations in two primary genes:

• ENG (Endoglin): Mutations in the ENG gene account for about 30-50% of HHT diagnoses. This gene provides instructions for making a protein called endoglin, which is found on the surface of cells lining blood vessels and plays a role in blood vessel formation and repair.
• ACVRL1 (Activin A receptor type II-like 1): Also known as ALK1, mutations in this gene are responsible for approximately 40-60% of HHT cases. The ACVRL1 gene provides instructions for making another protein involved in blood vessel development, particularly in response to growth factors that regulate cell growth and differentiation.

Together, mutations in ENG and ACVRL1 explain around 90% of all HHT cases. While these are the most common culprits, it's important to note that HHT can also be caused by mutations in other genes, although less frequently.

Other Genetic Factors

In a smaller percentage of cases (around 10%), HHT is caused by mutations in other genes, most notably:

• SMAD4: Mutations in the SMAD4 gene can cause HHT, and in some instances, can also be associated with juvenile polyposis syndrome, a condition characterized by numerous polyps in the gastrointestinal tract. This overlap highlights the complex interplay of genes in development.
• Other less common genes have also been implicated, but research is ongoing to fully understand their roles.

Inheritance Pattern: Autosomal Dominant

HHT is inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of the mutated gene from one parent to develop the condition. If a parent has HHT, each of their children has a 50% chance of inheriting the mutated gene and developing HHT. In about 20-30% of cases, HHT arises from a new (de novo) mutation in a person with no family history of the disorder. This means that individuals can develop HHT even if no one else in their family has it.

How Genetic Mutations Lead to HHT Symptoms

The genetic mutations in ENG, ACVRL1, or other related genes disrupt the normal processes of angiogenesis and vascular maturation. Specifically:

• Abnormal Vessel Formation: The mutated genes lead to the formation of blood vessels that lack the proper supportive structures, such as smooth muscle cells and elastic tissue. This makes their walls thin and weak.
• Arteriovenous Malformations (AVMs): Instead of the gradual transition from arteries to capillaries to veins, AVMs create direct, high-pressure connections between arteries and veins. These shunts bypass the capillary beds, which normally help regulate blood flow and pressure.
• Telangiectasias: These are small, dilated blood vessels that appear as red or purplish spots on the skin and mucous membranes (like inside the nose and mouth). They are essentially tiny AVMs.

When these fragile AVMs and telangiectasias are subjected to normal blood flow and pressure, they can easily rupture. The location of these malformations determines the specific symptoms a person experiences. For example:

• Nose and GI Tract: These areas have a rich blood supply and are subject to minor trauma (like nose blowing or digestion), making them common sites for bleeding.
• Lungs: Pulmonary AVMs can lead to shortness of breath and can allow blood clots or bacteria to bypass the lungs and travel to the brain, causing strokes or infections.
• Brain: Brain AVMs can cause headaches, seizures, and hemorrhagic strokes.
• Liver: Liver AVMs can lead to heart failure and other complications.

Understanding the genetic basis of HHT is crucial for diagnosis, genetic counseling, and the development of targeted therapies. While there is currently no cure for HHT, managing the symptoms and preventing complications relies heavily on early detection and appropriate medical care.